Post-vaccination Omicron infections induce broader immunity across antigenic space than prototype mRNA COVID-19 booster vaccination or primary infection

R: A Language and Environment for Statistical Computing

R Core Team (2000) · doi:10.32614/r.manuals · Cited by 355,706 · see citing works

In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector

Naldini, L., Blömer, U., Gallay, P., Ory, D., Mulligan, R., Gage, F. H., Verma, I. M., & Trono, D. (1996) · Science · doi:10.1126/science.272.5259.263 · Cited by 4,903 · see citing works

Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7

Wang, P., Nair, M. S., Liu, L., Iketani, S., Luo, Y., Guo, Y., Wang, M., Yu, J., Zhang, B., Kwong, P. D., et al. (2021) · Nature · doi:10.1038/s41586-021-03398-2 · Cited by 2,312 · see citing works

Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody Neutralization

(2021) · doi:10.21203/rs.3.rs-155394/v1 · Cited by 2,312 · see citing works

Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo

Zufferey, R., Nagy, D., Mandel, R. J., Naldini, L., & Trono, D. (1997) · Nature Biotechnology · doi:10.1038/nbt0997-871 · Cited by 1,977 · see citing works

Mapping the Antigenic and Genetic Evolution of Influenza Virus

Smith, D. J., Lapedes, A. S., de Jong, J. C., Bestebroer, T. M., Rimmelzwaan, G. F., Osterhaus, A. D. M. E., & Fouchier, R. A. M. (2004) · Science · doi:10.1126/science.1097211 · Cited by 1,868 · see citing works

SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion

Mlcochova, P., Kemp, S. A., Dhar, M. S., Papa, G., Meng, B., Ferreira, I. A. T. M., Datir, R., Collier, D. A., Albecka, A., Singh, S., et al. (2021) · Nature · doi:10.1038/s41586-021-03944-y · Cited by 1,337 · see citing works

BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection

Cao, Y., Yisimayi, A., Jian, F., Song, W., Xiao, T., Wang, L., Du, S., Wang, J., Li, Q., Chen, X., et al. (2022) · Nature · doi:10.1038/s41586-022-04980-y · Cited by 1,288 · see citing works

SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma

Wibmer, C. K., Ayres, F., Hermanus, T., Madzivhandila, M., Kgagudi, P., Oosthuysen, B., Lambson, B. E., de Oliveira, T., Vermeulen, M., van der Berg, K., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01285-x · Cited by 1,147 · see citing works

Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial

Gilbert, P. B., Montefiori, D. C., McDermott, A. B., Fong, Y., Benkeser, D., Deng, W., Zhou, H., Houchens, C. R., Martins, K., Jayashankar, L., et al. (2022) · Science · doi:10.1126/science.abm3425 · Cited by 1,137 · see citing works

Nextclade: clade assignment, mutation calling and quality control for viral genomes

Aksamentov, I., Roemer, C., Hodcroft, E. B., & Neher, R. A. (2021) · The Journal of Open Source Software · doi:10.21105/joss.03773 · Cited by 1,061 · see citing works

mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant

Garcia-Beltran, W. F., St. Denis, K. J., Hoelzemer, A., Lam, E. C., Nitido, A. D., Sheehan, M. L., Berrios, C., Ofoman, O., Chang, C. C., Hauser, B. M., et al. (2022) · Cell · doi:10.1016/j.cell.2021.12.033 · Cited by 1,045 · see citing works

Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa

Pulliam, J. R. C., van Schalkwyk, C., Govender, N., Gottberg, A. V., Cohen, C., Groome, M. J., Dushoff, J., Mlisana, K., & Moultrie, H. (2021) · doi:10.1101/2021.11.11.21266068 · Cited by 1,037 · see citing works

Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5

Wang, Q., Guo, Y., Iketani, S., Nair, M. S., Li, Z., Mohri, H., Wang, M., Yu, J., Bowen, A. D., Chang, J. Y., et al. (2022) · Nature · doi:10.1038/s41586-022-05053-w · Cited by 768 · see citing works

The Global Circulation of Seasonal Influenza A (H3N2) Viruses

Russell, C. A., Jones, T. C., Barr, I., Cox, N. J., Garten, R. J., Gregory, V., Gust, I. D., Hampson, A. W., Hay, A. J., Hurt, A. C., et al. (2008) · Science · doi:10.1126/science.1154137 · Cited by 729 · see citing works

Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies

Collier, D. A., De Marco, A., Ferreira, I. A. T. M., Meng, B., Datir, R. P., Walls, A. C., Kemp, S. A., Bassi, J., Pinto, D., Silacci-Fregni, C., et al. (2021) · Nature · doi:10.1038/s41586-021-03412-7 · Cited by 728 · see citing works

Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization

Wang, P., Casner, R. G., Nair, M. S., Wang, M., Yu, J., Cerutti, G., Liu, L., Kwong, P. D., Huang, Y., Shapiro, L., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.04.007 · Cited by 636 · see citing works

Homologous and Heterologous Covid-19 Booster Vaccinations

Atmar, R. L., Lyke, K. E., Deming, M. E., Jackson, L. A., Branche, A. R., Sahly, H. M. E., Rostad, C. A., Martin, J. M., Johnston, C., Rupp, R. E., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2116414 · Cited by 629 · see citing works

Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants

Accorsi, E. K., Britton, A., Fleming-Dutra, K. E., Smith, Z. R., Shang, N., Derado, G., Miller, J., Schrag, S. J., & Verani, J. R. (2022) · JAMA · doi:10.1001/jama.2022.0470 · Cited by 628 · see citing works

A Bivalent Omicron-Containing Booster Vaccine against Covid-19

Chalkias, S., Harper, C., Vrbicky, K., Walsh, S. R., Essink, B., Brosz, A., McGhee, N., Tomassini, J. E., Chen, X., Chang, Y., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2208343 · Cited by 627 · see citing works

Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, and BA.5

Hachmann, N. P., Miller, J. J., Collier, A.-R. Y., Ventura, J. D., Yu, J., Rowe, M., Bondzie, E. A., Powers, O. C., Surve, N., Hall, K., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2206576 · Cited by 530 · see citing works

Antibody landscapes after influenza virus infection or vaccination

Fonville, J. M., Wilks, S. H., James, S. L., Fox, A., Ventresca, M., Aban, M., Xue, L., Jones, T. C., H., L. N. M., Thái, P. Q., et al. (2014) · Science · doi:10.1126/science.1256427 · Cited by 475 · see citing works

mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant

Gruell, H., Vanshylla, K., Tober-Lau, P., Hillus, D., Schommers, P., Lehmann, C., Kurth, F., Sander, L. E., & Klein, F. (2022) · Nature Medicine · doi:10.1038/s41591-021-01676-0 · Cited by 410 · see citing works

Efficacy of a Fourth Dose of Covid-19 mRNA Vaccine against Omicron

Regev‐Yochay, G., Gonen, T., Gilboa, M., Mandelboim, M., Indenbaum, V., Amit, S., Meltzer, L., Asraf, K., Cohen, C., Fluss, R., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2202542 · Cited by 403 · see citing works

Emerging Variants of SARS-CoV-2 And Novel Therapeutics Against Coronavirus (COVID-19)

Aleem, A., Samad, A., & Slenker, A. K. (2021) · Europe PMC (PubMed Central) · Cited by 398 · see citing works

Protection by a Fourth Dose of BNT162b2 against Omicron in Israel

(2022) · doi:10.1056/nejmoa2201570 · Cited by 376 · see citing works

Immune boosting by B.1.1.529 ( Omicron) depends on previous SARS-CoV-2 exposure

Reynolds, C. J., Pade, C., Gibbons, J. M., Otter, A. D., Lin, K., Sandoval, D. M., Pieper, F. P., Butler, D. K., Liu, S., Joy, G., et al. (2022) · Science · doi:10.1126/science.abq1841 · Cited by 322 · see citing works

Global SARS-CoV-2 seroprevalence from January 2020 to April 2022: A systematic review and meta-analysis of standardized population-based studies

Bergeri, I., Whelan, M. G., Ware, H., Subissi, L., Nardone, A., Lewis, H. C., Li, Z., Ma, X., Valenciano, M., Cheng, B., et al. (2022) · PLoS Medicine · doi:10.1371/journal.pmed.1004107 · Cited by 313 · see citing works

Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting

Magen, O., Waxman, J. G., Makov-Assif, M., Vered, R., Dicker, D., Hernán, M. A., Lipsitch, M., Reis, B. Y., Balicer, R. D., & Dagan, N. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2201688 · Cited by 279 · see citing works

Rapid and inexpensive whole-genome sequencing of SARS-CoV-2 using 1200 bp tiled amplicons and Oxford Nanopore Rapid Barcoding

Freed, N. E., Vlková, M., Faisal, M., & Silander, O. (2020) · Biology Methods and Protocols · doi:10.1093/biomethods/bpaa014 · Cited by 268 · see citing works

Potential antigenic explanation for atypical H1N1 infections among middle-aged adults during the 2013–2014 influenza season

Linderman, S. L., Chambers, B. S., Zost, S. J., Parkhouse, K., Li, Y., Herrmann, C., Ellebedy, A. H., Carter, D. M., Andrews, S. F., Zheng, N., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1409171111 · Cited by 222 · see citing works

Neutralization of the SARS-CoV-2 Mu Variant by Convalescent and Vaccine Serum

Uriu, K., Kimura, I., Shirakawa, K., Takaori-Kondo, A., Nakada, T.-A., Kaneda, A., Nakagawa, S., & Sato, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2114706 · Cited by 214 · see citing works

mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron

Gagné, M., Moliva, J. I., Foulds, K. E., Andrew, S. F., Flynn, B. J., Werner, A. P., Wagner, D. A., Teng, I., Lin, B. C., Moore, C. A., et al. (2022) · Cell · doi:10.1016/j.cell.2022.03.038 · Cited by 206 · see citing works

Omicron BA.1 breakthrough infection drives cross-variant neutralization and memory B cell formation against conserved epitopes

Quandt, J., Muik, A., Salisch, N. C., Lui, B. G., Lutz, S., Krüger, K., Wallisch, A.-K., Adams‐Quack, P., Bacher, M., Finlayson, A., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abq2427 · Cited by 191 · see citing works

Neutralization of the SARS-CoV-2 Omicron BA.4/5 and BA.2.12.1 Subvariants

Qu, P., Faraone, J. N., Evans, J. P., Zou, X., Zheng, Y.-M., Carlin, C., Bednash, J. S., Lozanski, G., Mallampalli, R. K., Saif, L. J., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2206725 · Cited by 161 · see citing works

Antigenic cartography of SARS-CoV-2 reveals that Omicron BA.1 and BA.2 are antigenically distinct

Mykytyn, A. Z., Rissmann, M., Kok, A., Rosu, M. E., Schipper, D., Breugem, T. I., van den Doel, P. B., Chandler, F., Bestebroer, T., de Wit, M., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abq4450 · Cited by 153 · see citing works

Correlates of Protection, Thresholds of Protection, and Immunobridging among Persons with SARS-CoV-2 Infection

Khoury, D. S., Schlub, T. E., Cromer, D., Steain, M. C., Fong, Y., Gilbert, P. B., Subbarao, K., Triccas, J. A., Kent, S. J., & Davenport, M. P. (2023) · Emerging infectious diseases · doi:10.3201/eid2902.221422 · Cited by 148 · see citing works

Mapping SARS-CoV-2 antigenic relationships and serological responses

Wilks, S. H., Mühlemann, B., Shen, X., Türeli, S., LeGresley, E. B., Netzl, A., Caniza, M. A., Chacaltana-Huarcaya, J. N., Corman, V. M., Daniell, X. G., et al. (2023) · Science · doi:10.1126/science.adj0070 · Cited by 134 · see citing works

Establishment of a well-characterized SARS-CoV-2 lentiviral pseudovirus neutralization assay using 293T cells with stable expression of ACE2 and TMPRSS2

Neerukonda, S. N., Vassell, R. A., Herrup, R., Liu, S., Wang, T. T., Takeda, K., Yang, Y., Lin, T.-L., Wang, W., & Weiss, C. D. (2021) · PLoS ONE · doi:10.1371/journal.pone.0248348 · Cited by 130 · see citing works

SARS-CoV-2 BA.1 variant is neutralized by vaccine booster–elicited serum but evades most convalescent serum and therapeutic antibodies

Lusvarghi, S., Pollett, S. D., Neerukonda, S. N., Wang, W., Wang, R., Vassell, R. A., Epsi, N. J., Fries, A. C., Agan, B. K., Lindholm, D. A., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abn8543 · Cited by 130 · see citing works

Antigenic cartography using sera from sequence-confirmed SARS-CoV-2 variants of concern infections reveals antigenic divergence of Omicron

van der Straten, K., Guerra, D., van Gils, M. J., Bontjer, I., Caniels, T. G., van Willigen, H. D. G., Wynberg, E., Poniman, M., Burger, J. A., Bouhuijs, J. H., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.07.018 · Cited by 120 · see citing works

SARS-CoV-2 Omicron triggers cross-reactive neutralization and Fc effector functions in previously vaccinated, but not unvaccinated, individuals

Richardson, S. I., Madzorera, V. S., Spencer, H., Manamela, N. P., van der Mescht, M. A., Lambson, B. E., Oosthuysen, B., Ayres, F., Makhado, Z., Moyo-Gwete, T., et al. (2022) · Cell Host & Microbe · doi:10.1016/j.chom.2022.03.029 · Cited by 119 · see citing works

Antigenic evolution of dengue viruses over 20 years

Katzelnick, L. C., Escoto, A. C., Huang, A. T., García‐Carreras, B., Chowdhury, N., Berry, I. M., Chavez, C., Buchy, P., Duong, V., Dussart, P., et al. (2021) · Science · doi:10.1126/science.abk0058 · Cited by 80 · see citing works

BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants

Rössler, A., Netzl, A., Knabl, L., Schäfer, H., Wilks, S., Bante, D., Falkensammer, B., Borena, W., von Laer, D., Smith, D. J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-35312-3 · Cited by 77 · see citing works

Omicron subvariants escape antibodies elicited by vaccination and BA.2.2 infection

Lin, Y., Zhu, K.-L., Jiang, X., Wang, X., Zhan, B., Gao, H., Geng, X., Duan, L., Dai, E., & Ma, M. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00410-8 · Cited by 70 · see citing works

Immunogenicity and Safety of Beta-Adjuvanted Recombinant Booster Vaccine

Launay, O., Cachanado, M., Nguyen, L. B. L., Ninove, L., Lachâtre, M., Ghezala, I. B., Bardou, M., Schmidt‐Mutter, C., Felten, R., Lacombe, K., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2206711 · Cited by 68 · see citing works

Understanding “Hybrid Immunity”: Comparison and Predictors of Humoral Immune Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Infection (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) Vaccines

Epsi, N. J., Richard, S. A., Lindholm, D. A., Mende, K., Ganesan, A., Huprikar, N., Lalani, T., Fries, A. C., Maves, R. C., Colombo, R. E., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac392 · Cited by 55 · see citing works

Mapping the antigenic diversification of SARS-CoV-2Preprint

van der Straten, K., Guerra, D., van Gils, M. J., Bontjer, I., Caniels, T. G., van Willigen, H. D. G., Wynberg, E., Poniman, M., Burger, J. A., Bouhuijs, J. H., et al. (2022) · medRxiv · doi:10.1101/2022.01.03.21268582 · Cited by 46 · see citing works

Omicron BA.1 and BA.2 are antigenically distinct SARS-CoV-2 variantsPreprint

Mykytyn, A. Z., Rissmann, M., Kok, A., Rosu, M. E., Schipper, D., Breugem, T. I., van den Doel, P. B., Chandler, F. D., Bestebroer, T. M., de Wit, M., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.02.23.481644 · Cited by 43 · see citing works

COVID-19 Outcomes Among US Military Health System Beneficiaries Include Complications Across Multiple Organ Systems and Substantial Functional Impairment

Richard, S. A., Pollett, S. D., Lanteri, C. A., Millar, E. V., Fries, A. C., Maves, R. C., Utz, G. C., Lalani, T., Smith, A. G., Mody, R. M., et al. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab556 · Cited by 31 · see citing works

SARS-CoV-2 Delta Variant Displays Moderate Resistance to Neutralizing Antibodies and Spike Protein Properties of Higher Soluble ACE2 Sensitivity, Enhanced Cleavage and Fusogenic Activity

Neerukonda, S. N., Vassell, R. A., Lusvarghi, S., Wang, R., Echegaray, F., Bentley, L., Eakin, A. E., Erlandson, K. J., Katzelnick, L. C., Weiss, C. D., et al. (2021) · Viruses · doi:10.3390/v13122485 · Cited by 30 · see citing works

Antigen-based multiplex strategies to discriminate SARS-CoV-2 natural and vaccine induced immunity from seasonal human coronavirus humoral responsesPreprint

Laing, E. D., Sterling, S. L., Richard, S. A., Epsi, N. J., Coggins, S. A., Samuels, E. C., Phogat, S., Yan, L., Moreno, N., Coles, C. L., et al. (2021) · medRxiv · doi:10.1101/2021.02.10.21251518 · Cited by 29 · see citing works

Prospective Assessment of SARS-CoV-2 Seroconversion (PASS) study: an observational cohort study of SARS-CoV-2 infection and vaccination in healthcare workers

Jackson-Thompson, B. M., Goguet, E., Laing, E. D., Olsen, C. H., Pollett, S. D., Hollis-Perry, M., Maiolatesi, S. E., Illinik, L., Ramsey, K. F., Reyes, A. E., et al. (2021) · BMC Infectious Diseases · doi:10.1186/s12879-021-06233-1 · Cited by 23 · see citing works

Vaccination with SARS-CoV-2 variants of concern protects mice from challenge with wild-type virus

Amanat, F., Strohmeier, S., Meade, P. S., Dambrauskas, N., Mühlemann, B., Smith, D. J., Vigdorovich, V. I., Sather, D. N., Coughlan, L., & Krammer, F. (2021) · PLoS Biology · doi:10.1371/journal.pbio.3001384 · Cited by 19 · see citing works

Increased resistance of SARS-CoV-2 Lambda variant to antibody neutralization

Guo, H., Fan, Q., Song, S., Shen, S., Zhou, B., Wang, H., Cheng, L., Ge, X., Ju, B., & Zhang, Z. (2022) · Journal of Clinical Virology · doi:10.1016/j.jcv.2022.105162 · Cited by 12 · see citing works

Immune response and reactogenicity after immunization with two-doses of an experimental COVID-19 vaccine (CVnCOV) followed by a third-fourth shot with a standard mRNA vaccine (BNT162b2): RescueVacs multicenter cohort study

Ascaso-del-Rio, A., García‐Pérez, J., Pérez‐Olmeda, M., Arana‐Arri, E., Vergara, I., Pérez-Ingidua, C., Bermejo, M., de la Osa, M. C., Imaz-Ayo, N., Fernández, I. R., et al. (2022) · EClinicalMedicine · doi:10.1016/j.eclinm.2022.101542 · Cited by 9 · see citing works

Virological characteristics of the SARS-CoV-2 Omicron BA.2 subvariants, including BA.4 and BA.5

Kimura, I., Yamasoba, D., Tamura, T., Nao, N., Suzuki, T., Oda, Y., Mitoma, S., Ito, J., Nasser, H., Zahradník, J., et al. (2022) · Cell · doi:10.1016/j.cell.2022.09.018 · Cited by 286 · see citing works

Mapping SARS-CoV-2 antigenic relationships and serological responses

Wilks, S. H., Mühlemann, B., Shen, X., Türeli, S., LeGresley, E. B., Netzl, A., Caniza, M. A., Chacaltana-Huarcaya, J. N., Corman, V. M., Daniell, X. G., et al. (2023) · Science · doi:10.1126/science.adj0070 · Cited by 134 · see citing works

Protection against omicron (B.1.1.529) BA.2 reinfection conferred by primary omicron BA.1 or pre-omicron SARS-CoV-2 infection among health-care workers with and without mRNA vaccination: a test-negative case-control study

Carazo, S., Skowronski, D. M., Brisson, M., Sauvageau, C., Brousseau, N., Gilca, R., Ouakki, M., Barkati, S., Fafard, J., Talbot, D. C., et al. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00578-3 · Cited by 109 · see citing works

BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants

Rössler, A., Netzl, A., Knabl, L., Schäfer, H., Wilks, S., Bante, D., Falkensammer, B., Borena, W., von Laer, D., Smith, D. J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-35312-3 · Cited by 77 · see citing works

Antigenic mapping of emerging SARS-CoV-2 omicron variants BM.1.1.1, BQ.1.1, and XBB.1

Mykytyn, A. Z., Rosu, M. E., Kok, A., Rissmann, M., van Amerongen, G., GeurtsvanKessel, C. H., de Vries, R. D., Munnink, B. B. O., Smith, D. J., Koopmans, M., et al. (2023) · The Lancet Microbe · doi:10.1016/s2666-5247(22)00384-6 · Cited by 65 · see citing works

Characterizing SARS-CoV-2 neutralization profiles after bivalent boosting using antigenic cartography

Rössler, A., Netzl, A., Knabl, L., Bante, D., Wilks, S. H., Borena, W., von Laer, D., Smith, D. J., & Kimpel, J. (2023) · Nature Communications · doi:10.1038/s41467-023-41049-4 · Cited by 45 · see citing works

Hybrid Immunity to SARS-CoV-2 from Infection and Vaccination—Evidence Synthesis and Implications for New COVID-19 Vaccines

Spinardi, J., & Srivastava, A. K. (2023) · Biomedicines · doi:10.3390/biomedicines11020370 · Cited by 44 · see citing works

Low levels of neutralizing antibodies against XBB Omicron subvariants after BA.5 infection

Yang, H. J., Hong, W., Hong, L., He, C., Lei, W., Zhou, Y., Zhao, T., Alu, A., Ma, X., Li, J., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01495-4 · Cited by 44 · see citing works

Assessing COVID-19 vaccine effectiveness against Omicron subvariants: Report from a meeting of the World Health Organization

Feikin, D. R., Higdon, M. M., Andrews, N., Collie, S., Deloria Knoll, M., Kwong, J. C., Link-Gelles, R., Pilishvili, T., & Patel, M. K. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.02.020 · Cited by 36 · see citing works

Enhanced neutralization of SARS-CoV-2 variant BA.2.86 and XBB sub-lineages by a tetravalent COVID-19 vaccine booster

Wang, X., Jiang, S., Ma, W., Li, X., Wei, K., Xie, F., Zhao, C., Zhao, X., Wang, S., Li, C., et al. (2023) · Cell Host & Microbe · doi:10.1016/j.chom.2023.11.012 · Cited by 39 · see citing works

Antigenic evolution of SARS coronavirus 2

Mykytyn, A. Z., Fouchier, R. A. M., & Haagmans, B. L. (2023) · Current Opinion in Virology · doi:10.1016/j.coviro.2023.101349 · Cited by 36 · see citing works

Bivalent COVID-19 mRNA booster vaccination (BA.1 or BA.4/BA.5) increases neutralization of matched Omicron variants

Springer, D. N., Bauer, M. W., Medits, I., Camp, J. V., Aberle, S. W., Burtscher, C., Höltl, E., Weseslindtner, L., Stiasny, K., & Aberle, J. H. (2023) · npj Vaccines · doi:10.1038/s41541-023-00708-9 · Cited by 32 · see citing works

Durable reprogramming of neutralizing antibody responses following Omicron breakthrough infection

Lee, W. S., Tan, H., Reynaldi, A., Esterbauer, R., Koutsakos, M., Nguyen, J. T., Amarasena, T. H., Kent, H. E., Aggarwal, A., Turville, S. G., et al. (2023) · Science Advances · doi:10.1126/sciadv.adg5301 · Cited by 29 · see citing works

Combining antigenic data from public sources gives an early indication of the immune escape of emerging virus variantsPreprint

Netzl, A., Türeli, S., LeGresley, E. B., Mühlemann, B., Wilks, S., & Smith, D. J. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.31.474032 · Cited by 25 · see citing works

Antigenic cartography using variant-specific hamster sera reveals substantial antigenic variation among Omicron subvariants

Mühlemann, B., Trimpert, J., Walper, F., Schmidt, M. L., Jansen, J., Schroeder, S., Jeworowski, L. M., Beheim-Schwarzbach, J., Bleicker, T., Niemeyer, D., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2310917121 · Cited by 19 · see citing works

Virus neutralization assays for human respiratory syncytial virus using airway organoids

van Dijk, L. L. A., Rijsbergen, L. C., Tello-Rubio, B., Schmitz, K. S., Gommers, L., Comvalius, A. D., Havelaar, A. C., van Amerongen, G., Schepp, R. M., Lamers, M. M., et al. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-024-05307-y · Cited by 18 · see citing works

Strategy to develop broadly effective multivalent COVID-19 vaccines against emerging variants based on Ad5/35 platform

Chang, S., Kwang-Soo, S., Park, B., Park, S., Shin, J., Park, H. M., Jung, I. K., Jong Heon, K. I. M., Bae, S. E., Kim, J., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2313681121 · Cited by 18 · see citing works

Immune evasion of Omicron variants JN.1, KP.2, and KP.3 to the polyclonal and monoclonal antibodies from COVID-19 convalescents and vaccine recipients

Wu, Q., Wu, H., Hu, Y., Zheng, X., Chang, F., Liu, Y., Pan, Z., Wang, Q., Tang, F., Qian, J., et al. (2025) · Antiviral Research · doi:10.1016/j.antiviral.2025.106092 · Cited by 17 · see citing works

Emergent variant modeling of the serological repertoire to norovirus in young children

Lindesmith, L. C., Brewer-Jensen, P. D., Conrad, H., O’Reilly, K. M., Mallory, M. L., Kelly, D., Williams, R. J., Edmunds, W. J., Allen, D. J., Breuer, J., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.100954 · Cited by 15 · see citing works

Comparative analysis of SARS-CoV-2 neutralization titers reveals consistency between human and animal model serum and across assays

Mühlemann, B., Wilks, S. H., Baracco, L., Bekliz, M., Carreño, J. M., Corman, V. M., Davis-Gardner, M. E., Dejnirattisai, W., Diamond, M., Douek, D. C., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adl1722 · Cited by 18 · see citing works

Broad and potent neutralizing antibodies are elicited in vaccinated individuals following Delta/BA.1 breakthrough infection

Seow, J., Shalim, Z. A., Graham, C., Kimuda, S., Pillai, A., Lechmere, T., Kurshan, A., Khimji, A. M., Snell, L., Nebbia, G., et al. (2023) · mBio · doi:10.1128/mbio.01206-23 · Cited by 10 · see citing works

Nonhuman primate antigenic cartography of SARS-CoV-2

Rössler, A., Netzl, A., Lasrado, N., Chaudhari, J., Mühlemann, B., Wilks, S. H., Kimpel, J., Smith, D. J., & Barouch, D. H. (2025) · Cell Reports · doi:10.1016/j.celrep.2024.115140 · Cited by 13 · see citing works

SARS-CoV-2 serotyping based on spike antigenicity and its implications for host immune evasion

Ruan, W., Gao, P., Qu, X., Jiang, J., Zhao, Z., Qiao, S., Zhang, H., Yang, T., Li, D., Du, P., et al. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2025.105634 · Cited by 13 · see citing works

A Recombinant Protein XBB.1.5 RBD/Alum/CpG Vaccine Elicits High Neutralizing Antibody Titers against Omicron Subvariants of SARS-CoV-2

Thimmiraju, S. R., Adhikari, R., Villar, M. J., Lee, J., Liu, Z., Kundu, R. T., Chen, Y., Sharma, S., Ghei, K., Keegan, B. P., et al. (2023) · Vaccines · doi:10.3390/vaccines11101557 · Cited by 11 · see citing works

Immune escape of BA.2.86 is comparable to XBB subvariants from the plasma of BA.5‐ and BA.5‐XBB‐convalescent subpopulations

Yang, X., Wang, Y., Liang, Z., Cui, T., Chen, D., Li, G., Xu, H. Y., Liu, S., Zhong, N., Huang, W., et al. (2024) · Journal of Medical Virology · doi:10.1002/jmv.29417 · Cited by 12 · see citing works

Human and hamster sera correlate well in identifying antigenic drift among SARS-CoV-2 variants, including JN.1

Wang, W., Bhushan, G. L., Paz, S., Stauft, C. B., Selvaraj, P., Goguet, E., Bishop‐Lilly, K. A., Subramanian, R., Vassell, R. A., Lusvarghi, S., et al. (2024) · Journal of Virology · doi:10.1128/jvi.00948-24 · Cited by 10 · see citing works

Neutralization of omicron subvariants and antigenic cartography following multiple COVID 19 vaccinations and repeated omicron non JN.1 or JN.1 infections

Suntronwong, N., Kanokudom, S., Duangchinda, T., Chantima, W., Pakchotanon, P., Klinfueng, S., Puenpa, J., Thatsanathorn, T., Wanlapakorn, N., & Poovorawan, Y. (2025) · Scientific Reports · doi:10.1038/s41598-024-84138-0 · Cited by 10 · see citing works

Longitudinal effects of SARS-CoV-2 breakthrough infection on imprinting of neutralizing antibody responses

Einhauser, S., Asam, C., Weps, M., Senninger, A., Peterhoff, D., Bauernfeind, S., Asbach, B., Carnell, G., Heeney, J. L., Wytopil, M., et al. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105438 · Cited by 9 · see citing works

Evaluation of the cross reactivity of neutralising antibody response in vaccinated human and convalescent hamster sera against SARS-CoV-2 variants up to and including JN.1 using an authentic virus neutralisation assayPreprint

Coombes, N. S., Bewley, K. R., Duff, Y. L., Alami-Rahmouni, N., Ryan, K. A., Kempster, S. L., Ferguson, D., Davies, E. R., Weldon, T. M., Cross, E. S., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.10.21.563398 · Cited by 9 · see citing works

Antigenic Cartography Indicates That the Omicron BA.1 and BA.4/BA.5 Variants Remain Antigenically Distant to Ancestral SARS-CoV-2 after Sputnik V Vaccination Followed by Homologous (Sputnik V) or Heterologous (Comirnaty) Revaccination

Astakhova, E. A., Morozov, A. A., Byazrova, M. G., Sukhova, M. M., Mikhailov, A. A., Minnegalieva, A. R., Gorchakov, A. A., & Filatov, A. V. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310493 · Cited by 8 · see citing works

Cross-protection and cross-neutralization capacity of ancestral and VOC-matched SARS-CoV-2 adenoviral vector-based vaccines

Vinzón, S. E., Lopez, M. V., Cafferata, E. G. A., Soto, A. S., Berguer, P. M., Vázquez, L., Nusblat, L., Pontoriero, A., Belotti, E. M., Salvetti, N. R., et al. (2023) · npj Vaccines · doi:10.1038/s41541-023-00737-4 · Cited by 8 · see citing works

A bivalent COVID-19 mRNA vaccine elicited broad immune responses and protection against Omicron subvariants infection

Liu, J., Wang, L., Kurtesi, A., Budylowski, P., Potts, K. G., Menon, H., Tan, Y., Samaan, P., Liu, X., Wang, Y., et al. (2025) · npj Vaccines · doi:10.1038/s41541-025-01062-8 · Cited by 7 · see citing works

Reduced cross-protective potential of Omicron compared to ancestral SARS-CoV-2 spike vaccines against potentially zoonotic coronaviruses

Renner, T. M., Stuible, M., Cass, B., Perret, S., Guimond, J., Lord‐Dufour, S., McCluskie, M. J., Durocher, Y., & Akache, B. (2024) · npj Viruses · doi:10.1038/s44298-024-00067-9 · Cited by 6 · see citing works

Survey of white-footed mice (Peromyscus leucopus) in Connecticut, USA reveals low SARS-CoV-2 seroprevalence and infection with divergent betacoronaviruses

Earnest, R., Hahn, A. M., Feriancek, N. M., Brandt, M., Filler, R. B., Zhao, Z., Breban, M. I., Vogels, C. B. F., Chen, N. F. G., Koch, R. T., et al. (2023) · npj Viruses · doi:10.1038/s44298-023-00010-4 · Cited by 7 · see citing works

Safety, immunogenicity, and protective effective of inhaled COVID‐19 vaccines: A systematic review and meta‐analysis

Gao, S., Li, R., & Cheng, M.-Q. (2024) · Journal of Medical Virology · doi:10.1002/jmv.29625 · Cited by 6 · see citing works

Antigenic cartography using hamster sera identifies SARS-CoV-2 JN.1 evasion seen in human XBB.1.5 booster seraPreprint

Wang, W., Bhushan, G. L., Paz, S., Stauft, C. B., Selvaraj, P., Goguet, E., Bishop‐Lilly, K. A., Subramanian, R., Vassell, R. A., Lusvarghi, S., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.04.05.588359 · Cited by 6 · see citing works

New Insights Into an Old Vaccine: Potency and Breadth of Neutralizing Antibodies Elicited by Yellow Fever Vaccine 17D Are Boosted by Heterologous Orthoflavivirus Infection

Coulter, F. J., Micheleti, C., Estrada, A. E., Luo, S., Osman, S. R., Nix, C. D., Hu, S. Y., Sampouw, S. M., Kareko, B. W., Naleway, A. L., et al. (2026) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiag077 · Cited by 5 · see citing works

Bioinformatics and molecular biology tools for diagnosis, prevention, treatment and prognosis of COVID-19

Meira, D. D., Zetum, A. S. S., Casotti, M. C., da Silva, D. R. C., de Araújo, B. C., Vicente, C. R., Duque, D. D. A., Campanharo, B. P., Garcia, F. M., Campanharo, C. V., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e34393 · Cited by 5 · see citing works

Expanded immune imprinting and neutralization spectrum by hybrid immunization following breakthrough infections with SARS-CoV-2 variants after three-dose vaccination

Jia, T., Wang, F., Chen, Y., Liao, G., Xu, Q., Chen, J., Wu, J., Li, N., Wang, L., Yuan, L., et al. (2024) · Journal of Infection · doi:10.1016/j.jinf.2024.106362 · Cited by 7 · see citing works

Measuring Variant-Specific Neutralizing Antibody Profiles after Bivalent SARS-CoV-2 Vaccinations Using a Multivariant Surrogate Virus Neutralization Microarray

Springer, D. N., Höltl, E., Prüger, K., Puchhammer‐Stöckl, E., Aberle, J. H., Stiasny, K., & Weseslindtner, L. (2024) · Vaccines · doi:10.3390/vaccines12010094 · Cited by 5 · see citing works

Primary SARS-CoV-2 variant of concern infections elicit broad antibody Fc-mediated effector functions and memory B cell responses

van der Straten, K., Guerra, D., Kerster, G., Claireaux, M. A. F., Grobben, M., Schriek, A. I., Boyd, A. C., van Rijswijk, J., Tejjani, K., Eggink, D., et al. (2024) · PLoS Pathogens · doi:10.1371/journal.ppat.1012453 · Cited by 4 · see citing works

Enhanced neutralization of SARS-CoV-2 XBB sub-lineages and BA.2.86 by a tetravalent COVID-19 vaccine boosterPreprint

Wang, X., Jiang, S., Ma, W., Li, X., Wei, K., Xie, F., Zhao, C., Zhao, X., Li, C., Qiao, R., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.09.14.557682 · Cited by 4 · see citing works

Comparative Analysis of SARS-CoV-2 Antigenicity across Assays and in Human and Animal Model SeraPreprint

Mühlemann, B., Wilks, S., Baracco, L., Bekliz, M., Carreño, J. M., Corman, V. M., Davis-Gardner, M. E., Dejnirattisai, W., Diamond, M., Douek, D. C., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.09.27.559689 · Cited by 4 · see citing works

Context-flexible cartography with Siamese topological neural networks

Hartono, P. (2024) · Discover Artificial Intelligence · doi:10.1007/s44163-023-00098-w · Cited by 3 · see citing works

Population shift in antibody immunity following the emergence of a SARS-CoV-2 variant of concern

Bhiman, J. N., Madzorera, V. S., Mkhize, Q., Scheepers, C., Hermanus, T., Ayres, F., Makhado, Z., Moyo-Gwete, T., Crowther, C. E., Singh, B., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-89940-y · Cited by 3 · see citing works

A critical residue in a conserved RBD epitope determines neutralization breadth of pan-sarbecovirus antibodies with recurring YYDRxxG motifs

Stein, S. C., Ssebyatika, G. L., Benecke, T., Stroh, L. J., Rajak, M. K., Vollmer, B., Menz, S., Waldmann, J.-Y., Tipp, S. N., Ochulor, O., et al. (2025) · mBio · doi:10.1128/mbio.00606-25 · Cited by 3 · see citing works

Antibody responses in blood and saliva post COVID-19 bivalent booster do not reveal an Omicron BA.4/BA.5- specific response

Baker, R., Lawlor, R. G., Smith, M. P., Price, J., Eaton, A., Lover, A. A., Alfandari, D., Reinhart, P. H., Arcaro, K. F., & Osborne, B. A. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1401209 · Cited by 3 · see citing works

Continuous Tracking for Effective Tackling: Ad5/35 Platform‐Based JN1 Lineage Vaccines Development in Response to Evolving SARS‐CoV‐2 Variants

Chang, S., Shin, J., Park, S., Park, H. M., Jong Heon, K. I. M., Kim, T., Jung, I. K., Song, B., Shin, K., Park, B., et al. (2025) · Journal of Medical Virology · doi:10.1002/jmv.70206 · Cited by 3 · see citing works

Durable reprogramming of neutralising antibody responses following breakthrough Omicron infectionPreprint

Lee, W. S., Tan, H., Reynaldi, A., Esterbauer, R., Koutsakos, M., Nguyen, J. T., Amarasena, T. H., Kent, H. E., Aggarwal, A., Turville, S. G., et al. (2023) · medRxiv · doi:10.1101/2023.02.19.23286159 · Cited by 3 · see citing works

SARS-CoV-2 in Animal Companions: A Serosurvey in Three Regions of Southern Italy

Bianco, A., Bortolami, A., Miccolupo, A., Sottili, R., Ghergo, P., Castellana, S., Sambro, L. D., Capozzi, L., Pagliari, M., Bonfante, F., et al. (2023) · Life · doi:10.3390/life13122354 · Cited by 2 · see citing works

High transmission of endemic human coronaviruses before and during the COVID-19 pandemic in adolescents in Cebu, Philippines

Joseph, J. O., Ylade, M. C., Daag, J. V., Aogo, R. A., Crisostomo, M. V., Mpingabo, P. I., Premkumar, L., Deen, J. L., & Katzelnick, L. C. (2024) · BMC Infectious Diseases · doi:10.1186/s12879-024-09672-8 · Cited by 2 · see citing works

Challenges in Humoral Immune Response to Adeno-Associated Viruses Determination

Naumova, D. A., Krokunova, T., Maksimov, D. O., Mityaeva, O. N., Astakhova, E. A., & Volchkov, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26020816 · Cited by 2 · see citing works

Comparative Interactome Profiling of Nonstructural Protein 3 Across SARS-CoV-2 Variants Emerged During the COVID-19 Pandemic

Lopez, V. G., & Plate, L. (2025) · Viruses · doi:10.3390/v17030447 · Cited by 6 · see citing works

Role of prior immunity in binding to spike of “future” Omicron subvariants

Biswas, D., Mahalingam, G., Subaschandrabose, R. K., Priya, S., Ramachandran, R., Suresh, S., Mathivanan, T. V., Balu, N. V., Selvaraj, K., Nellickal, A. J., et al. (2024) · Indian Journal of Medical Microbiology · doi:10.1016/j.ijmmb.2024.100615 · Cited by 2 · see citing works

The infectious diseases clinical research program acute respiratory infection repository protocol: Opportunities to understand current and future epidemics

Pollett, S. D., Colombo, R. E., Richard, S. A., Lalani, T., Barton, B., Malloy, A. M. W., Fries, A. C., Parmelee, E., Merritt, S., Fritschlanski, M., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0317065 · Cited by 1 · see citing works

Antigenic Cartography of SARS-CoV-2

Astakhova, E. A., Morozov, A. A., Vavilova, J. D., & Filatov, A. V. (2024) · Biochemistry (Moscow) · doi:10.1134/s0006297924050079 · Cited by 1 · see citing works

SARS-CoV-2 variant replacement constrains vaccine-specific viral diversification

Dearlove, B. L., Fries, A. C., Epsi, N. J., Richard, S. A., Ganesan, A., Huprikar, N., Lindholm, D. A., Mende, K., Colombo, R. E., Colombo, C. J., et al. (2024) · Virus Evolution · doi:10.1093/ve/veae071 · Cited by 1 · see citing works

Broad and potent neutralizing mAbs are elicited in vaccinated individuals following Delta/BA.1 breakthrough infectionPreprint

Seow, J., Shalim, Z. A., Graham, C., Kimuda, S., Pillai, A., Lechmere, T., Kurshan, A., Khimji, A. M., Snell, L., Nebbia, G., et al. (2023) · bioRxiv · doi:10.1101/2023.03.30.534872 · Cited by 1 · see citing works

Humoral immune response to omicron infection in long-term Wuhan-Hu-1-imprinted populationPreprint

Lü, Y., Zhu, Y., Zheng, Y., Tang, L., Chen, H., Zhou, C.-L., Luo, J., Yang, X., Yu, L., Hu, Q., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3024491/v1 · Cited by 1 · see citing works

Equivalent Binding Of Sera From Omicron And Delta Period To Future Omicron SubvariantsPreprint

Biswas, D., Mahalingam, G., Subaschandrabose, R. K., Priya, S., Ramachandran, R., Suresh, S., Mathivanan, T. V., Balu, N. V., Selvaraj, K., Nellickal, A. J., et al. (2023) · medRxiv · doi:10.1101/2023.08.04.23293670 · Cited by 1 · see citing works

Survey of white-footed mice in Connecticut, USA reveals low SARS-CoV-2 seroprevalence and infection with divergent betacoronavirusesPreprint

Earnest, R., Hahn, A. M., Feriancek, N. M., Brandt, M., Filler, R. B., Zhao, Z., Breban, M. I., Vogels, C. B. F., Chen, N. F. G., Koch, R. T., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.09.22.559030 · Cited by 1 · see citing works

Antigenic cartography of SARS-CoV-2 (review)

Astakhova, E. A., Morozov, A. A., Vavilova, J. D., & Filatov, A. V. (2024) · Biochemistry (Moscow) · doi:10.31857/s0320972524050075

New insights into an old vaccine: potency and breadth of neutralizing antibodies elicited by the yellow fever vaccine 17D are boosted by heterologous Orthoflavivirus infectionPreprint

Coulter, F. J., Estrada, A. E., Micheletti, C. A., Luo, S., Osman, S. R., Nix, C. D., Hu, S., Naleway, A. L., & Messer, W. B. (2025) · medRxiv · doi:10.1101/2025.07.31.25332277

Combining antigenic data from public sources gives an early indication of the immune escape of emerging virus variants

Netzl, A., Türeli, S., LeGresley, E. B., Mühlemann, B., Wilks, S. H., & Smith, D. J. (2025) · Scientific Reports · doi:10.1038/s41598-025-19578-3 · Cited by 22 · see citing works

Immunogenic relationship mapping supports a minimal-set trivalent vaccine strategy for broad sarbecovirus protection

Sun, Y., Cheng, Z., Wu, X., Bai, Y., Zhao, L., Xiang, H., Huang, W., & Nie, J. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02565-5

SARS-CoV-2 vaccination and infection elicit cross-neutralizing responses against clade 3 and 4 sarbecoviruses

Schmidt, S. D., Subramanian, R., Basappa, M., Carroll, R., Rexhepaj, M., Posavad, C. M., Liao, J. A., Bohl, J. A., Chowdhury, A., Spaulding, A. B., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-71662-y

Co-administration of intranasal parainfluenza virus vaccines expressing antigenically distinct SARS-CoV-2 S antigens elicits broad and durable immunity in hamsters

Park, H.-S., Matsuoka, Y., Santos, C., Duncan, E. F., Kaiser, J. A., Yang, L.-J., Luongo, C., Liu, X.-Q., Teng, I.-T., Kwong, P. D., et al. (2026) · Journal of Virology · doi:10.1128/jvi.00938-26

Estimating SARS-CoV-2 reinfection frequency and infection incidence: A modeling study

Qiao, J., Okada, Y., & Nishiura, H. (2026) · Epidemics · doi:10.1016/j.epidem.2026.100956

Different Neutralization Profiles After Primary SARS-CoV-2 Omicron BA.1 and BA.2 Infections

Medits, I., Springer, D. N., Graninger, M., Camp, J. V., Höltl, E., Aberle, S. W., Traugott, M. T., Hoepler, W., Deutsch, J., Lammel, O., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.946318 · Cited by 36 · see citing works

Neutralization of omicron subvariants and antigenic cartography following multiple COVID 19 vaccinations and repeated omicron non JN.1 or JN.1 infections

Suntronwong, N., Kanokudom, S., Duangchinda, T., Chantima, W., Pakchotanon, P., Klinfueng, S., Puenpa, J., Thatsanathorn, T., Wanlapakorn, N., & Poovorawan, Y. (2025) · Scientific Reports · doi:10.1038/s41598-024-84138-0 · Cited by 10 · see citing works

Neutralization capacity of antibodies elicited through homologous or heterologous infection or vaccination against SARS-CoV-2 VOCs

Bekliz, M., Adea, K., Vetter, P., Eberhardt, C. S., Hosszu-Fellous, K., Vu, D., Puhach, O., Essaidi-Laziosi, M., Waldvogel‐Abramowski, S., Stephan, C., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31556-1 · Cited by 85 · see citing works

Characterizing SARS-CoV-2 neutralization profiles after bivalent boosting using antigenic cartography

Rössler, A., Netzl, A., Knabl, L., Bante, D., Wilks, S. H., Borena, W., von Laer, D., Smith, D. J., & Kimpel, J. (2023) · Nature Communications · doi:10.1038/s41467-023-41049-4 · Cited by 45 · see citing works

Neutralization Profile after Recovery from SARS-CoV-2 Omicron Infection

Rössler, A., Knabl, L., von Laer, D., & Kimpel, J. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2201607 · Cited by 95 · see citing works